immatics biotechnologies forms a pharma alliances with Roche for a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics for $1.017billion.
It will focus on the research, clinical development and commercialisation of a number of new tumour-associated peptide (TUMAP)-based cancer vaccine candidates and other immunotherapies in oncology, targeting primarily gastric, prostate and non-small cell lung cancer.
The most advanced cancer vaccine candidate covered by the agreement is IMA942, for the treatment of gastric cancer, which is ready for phase I trials.
In this pharma alliances Roche will be responsible for the clinical development and commercialisation of all of the immunotherapies generated by immatics as a result of this collaboration.
immatics will conduct research on behalf of Roche using its unique XPRESIDENT technology platform to identify novel and relevant TUMAP candidates for the development of cancer vaccines and other compounds targeting cancer peptide antigens, primarily in gastric, prostate and non-small cell lung cancer.
immatics will receive an upfront payment of $17 million and committed research funding plus potential milestone payments that could reach values in excess of $1 billion and royalties across three cancer indications, based on sales of the cancer vaccines and immunotherapies resulting from this agreement.
Read the full press release at PR Newswire.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Roche
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity